Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Código da empresaRYTM
Nome da EmpresaRhythm Pharmaceuticals Inc
Data de listagemOct 05, 2017
Fundado em2013
CEO- -
Número de funcionários283
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 05
Endereço222 Berkeley Street
CidadeBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02116
Telefone18572644280
Sitehttps://rhythmtx.com/
Código da empresaRYTM
Data de listagemOct 05, 2017
Fundado em2013
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados